Hepato-gastroenterology · 2012
A pilot trial of S-1 plus irinotecan chemotherapy for esophageal adenocarcinoma.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Nakajima Yasuaki, Fujiwara Naoto, Ryotokuji Tairo, Ohta Shunsuke, Okada Takuya, Miyawaki Yutaka, Hoshino Akihiro, Jirawat Swangsri, Tokairin Yutaka, Kawada Kenro, Nishikage Tetsuro, Nagai Kagami, Kawano Tatsuyuki
Аннотация
BACKGROUND/AIMS: This study investigated the clinical efficacy and toxicity of the combination chemotherapy using S-1 plus irinotecan for esophageal adenocarcinoma.
METHODOLOGY: This study included 10 patients with histologically confirmed adenocarcinoma of the esophagus or esophagogastric junction between April 2005 and August 2011. S-1 was administered orally at a dose of 80 mg/m²/day from day 1 to 14 and irinotecan was given intravenously on day 1 and 8 at a dose of 80 mg/m².
RESULTS: A total of 65 cycles were administered and the response rate was 62.5%. The 50% progression-free survival period and the 50% overall survival period for all of the patients was 8.4 months and 19.1 months, respectively and 5.9 months and 16.3 months for the 8 patients with unresectable or recurrent tumors, respectively. The 2 patients that received adjuvant chemotherapy demonstrated a prophylactic effect for the post-operative recurrence. On the other hand, this therapy showed no severe non-hematological toxicity and only 20% experienced grade 3 neutropenia. As a result, the treatment regimen could generally be performed in an outpatient basis.
CONCLUSIONS: The combination chemotherapy using S-1 and irinotecan showed tolerable clinical efficacy in terms of the response rate, survival and toxicity for esophageal adenocarcinoma.
METHODOLOGY: This study included 10 patients with histologically confirmed adenocarcinoma of the esophagus or esophagogastric junction between April 2005 and August 2011. S-1 was administered orally at a dose of 80 mg/m²/day from day 1 to 14 and irinotecan was given intravenously on day 1 and 8 at a dose of 80 mg/m².
RESULTS: A total of 65 cycles were administered and the response rate was 62.5%. The 50% progression-free survival period and the 50% overall survival period for all of the patients was 8.4 months and 19.1 months, respectively and 5.9 months and 16.3 months for the 8 patients with unresectable or recurrent tumors, respectively. The 2 patients that received adjuvant chemotherapy demonstrated a prophylactic effect for the post-operative recurrence. On the other hand, this therapy showed no severe non-hematological toxicity and only 20% experienced grade 3 neutropenia. As a result, the treatment regimen could generally be performed in an outpatient basis.
CONCLUSIONS: The combination chemotherapy using S-1 and irinotecan showed tolerable clinical efficacy in terms of the response rate, survival and toxicity for esophageal adenocarcinoma.
Предметные рубрики MeSH
AdenocarcinomaAdministration, OralAdultAgedAntineoplastic Combined Chemotherapy ProtocolsCamptothecinChemotherapy, AdjuvantDisease-Free SurvivalDrug Administration ScheduleDrug CombinationsEsophageal NeoplasmsEsophagectomyEsophagogastric JunctionFemaleHumansInfusions, IntravenousIrinotecanMaleMiddle AgedOxonic AcidPilot ProjectsSurvival AnalysisTegafurTime FactorsTreatment Outcome